Traumatic Brain Injury — Part 3: ICP Management & Surgical Indications
ICP monitoring indications, ICP and CPP targets, complete tiered ICP management protocol with dosing, hyperosmolar therapy, EVD drainage, decompressive craniectomy (DECRA, RESCUEicp), barbiturate coma, and surgical indications for epidural hematoma, subdural hematoma, depressed skull fracture, and posterior fossa lesions.
1. Intracranial Pressure Monitoring
1.1 Pathophysiology of Elevated ICP
The Monro-Kellie doctrine states that the intracranial compartment is a fixed volume composed of brain parenchyma (~80%), cerebrospinal fluid (~10%), and blood (~10%). An increase in any one component must be compensated by a decrease in another, or intracranial pressure will rise. In TBI, compensation mechanisms (CSF displacement into the spinal canal, reduction in cerebral venous blood volume) are rapidly exhausted, after which small increases in volume produce large increases in ICP (steep portion of the pressure-volume curve).1
Normal ICP values:
| Population | Normal ICP |
|---|---|
| Adults (supine) | 7–15 mmHg |
| Children | 3–7 mmHg |
| Infants | 1.5–6 mmHg |
1.2 Indications for ICP Monitoring
ICP monitoring is recommended for the following patients with severe TBI.1 2
| Indication | Evidence Level |
|---|---|
| GCS 3–8 after resuscitation AND abnormal CT (hematoma, contusion, swelling, compressed cisterns, herniation) | Level IIB |
| GCS 3–8 after resuscitation AND normal CT if ≥ 2 of the following risk factors are present: age > 40 years, unilateral or bilateral motor posturing, SBP < 90 mmHg | Level III |
| Moderate TBI (GCS 9–12) with large contusions or clinical deterioration | Expert recommendation (not addressed in BTF guidelines directly) |
BEST:TRIP Trial Context: The BEST:TRIP trial (2012) compared ICP monitoring-based management to clinical examination and serial CT-based management in severe TBI patients in Bolivia. There was no mortality difference between groups. However, this does NOT mean ICP monitoring is unnecessary — the imaging-clinical examination protocol group received MORE aggressive therapies empirically. The trial demonstrated that protocol-based care is important, not that ICP monitoring lacks value. ICP monitoring remains the standard of care in resource-adequate settings.3
1.3 Types of ICP Monitors
| Device | Location | Advantages | Disadvantages |
|---|---|---|---|
| External ventricular drain (EVD) | Lateral ventricle (typically right, non-dominant) | Gold standard; allows both ICP monitoring AND therapeutic CSF drainage; can be recalibrated | Infection risk (5–15%); ventriculostomy hemorrhage (1–2%); placement may be difficult with compressed ventricles |
| Intraparenchymal monitor (e.g., Camino, Codman Microsensor) | Brain parenchyma (typically right frontal) | Easy to place; lower infection rate than EVD; reliable waveform | Cannot drain CSF; cannot be recalibrated after placement (zero drift ± 2–3 mmHg) |
| Subdural/epidural bolt | Subdural or epidural space | Less invasive | Less accurate than EVD or intraparenchymal; higher artifact rate |
| Noninvasive (optic nerve sheath diameter, transcranial Doppler) | External | Noninvasive; rapid assessment | Less accurate; cannot guide continuous management; screening tools only |
Practical Recommendation: An EVD is preferred when therapeutic CSF drainage is anticipated (most severe TBI patients). An intraparenchymal monitor is reasonable when CSF drainage is not anticipated or ventricles are too small/compressed for catheter placement.2
1.4 ICP Waveform Interpretation
| Waveform Component | Description | Clinical Significance |
|---|---|---|
| P1 (percussion wave) | Sharp arterial pulsation peak | Normally the tallest component |
| P2 (tidal wave) | Brain compliance wave | When P2 > P1, indicates decreased intracranial compliance (early warning of rising ICP before numeric elevation) |
| P3 (dicrotic wave) | Venous pulsation (dicrotic notch) | Normally the smallest component |
| Lundberg A waves (plateau waves) | Sustained ICP elevations to 50–100 mmHg lasting 5–20 minutes | Pathological; indicates exhausted compliance; requires urgent treatment |
| Lundberg B waves | Rhythmic oscillations of ICP (0.5–2/min) with amplitude 20–50 mmHg | May indicate decreased compliance; associated with REM sleep; clinical significance debated |
| Lundberg C waves | Small oscillations (4–8/min) with amplitude < 20 mmHg | Normal; related to respiratory and cardiovascular rhythms |
2. ICP and CPP Targets
2.1 ICP Threshold
| Recommendation | Value | Evidence Level |
|---|---|---|
| Treat ICP above | 22 mmHg | Level IIB1 |
| Previous threshold | 20 mmHg (used in earlier guideline editions) | Historical |
| Duration-based thresholds | Sustained ICP > 22 mmHg for > 5 minutes warrants treatment; brief spikes with coughing/suctioning may not require intervention if they resolve | Expert recommendation |
| ICP dose (burden) | Cumulative time × magnitude of ICP elevation above 22 mmHg; higher ICP dose correlates with worse outcomes | Emerging metric |
2.2 Cerebral Perfusion Pressure (CPP) Targets
CPP = MAP − ICP
| Recommendation | Value | Evidence Level |
|---|---|---|
| Target CPP range | 60–70 mmHg | Level IIB1 |
| Minimum CPP | ≥ 60 mmHg | Level IIB — CPP < 60 is associated with ischemia and worse outcomes |
| Maximum CPP | ≤ 70 mmHg (avoid aggressive CPP augmentation above 70) | Level IIB — CPP > 70 increases risk of ARDS from excessive vasopressor/fluid use without improving outcomes |
| Autoregulation-guided CPP (CPPopt) | The “optimal CPP” can be individualized using pressure reactivity index (PRx) monitoring; associated with improved outcomes when CPP is maintained near CPPopt | Emerging evidence; not yet standard of care4 |
Critical Point: Do NOT attempt to achieve CPP targets by allowing ICP to remain elevated while augmenting MAP with vasopressors. The priority is to treat elevated ICP first, then optimize MAP to achieve the CPP target.1
3. Tiered Approach to ICP Management
The management of elevated ICP follows a stepwise, escalating approach. Treatment begins with the least invasive and lowest-risk interventions (Tier 0) and progresses through increasingly aggressive therapies as needed.1 2 5
3.0 Tier 0 — Foundational Measures (All Patients with Severe TBI)
These measures should be implemented for ALL patients with severe TBI, regardless of ICP values.
| Intervention | Details |
|---|---|
| Head of bed elevation | 30° with head in neutral midline position |
| Avoid jugular venous obstruction | Loosen cervical collar; avoid circumferential neck tape; avoid tight endotracheal tube ties; avoid internal jugular central line placement on the side of the lesion |
| Sedation and analgesia | Propofol infusion 20–75 mcg/kg/min OR midazolam 0.02–0.1 mg/kg/hr + fentanyl 25–200 mcg/hr. Goal: RASS −3 to −4 |
| Normothermia | Target core temperature 36–37.5°C. Treat fever aggressively (acetaminophen, surface or intravascular cooling) |
| Normocapnia | PaCO2 35–40 mmHg |
| Normonatremia to mild hypernatremia | Serum Na 140–150 mEq/L (avoid hyponatremia, which worsens cerebral edema) |
| Euvolemia | Avoid hypovolemia and hypotension |
| Normoglycemia | Blood glucose 100–180 mg/dL |
| Seizure prophylaxis | Levetiracetam or phenytoin for 7 days (see Part 2) |
| Treat pain and agitation | Uncontrolled pain and agitation significantly raise ICP |
| DVT prophylaxis | Mechanical prophylaxis immediately; pharmacologic when hemorrhage is stable |
3.1 Tier 1 — First-Line ICP-Lowering Therapies
Initiate when ICP remains > 22 mmHg despite Tier 0 measures.
3.1.1 CSF Drainage via EVD
| Parameter | Detail |
|---|---|
| Method | Open EVD to drain CSF against gravity; drainage set at 10–15 cmH2O above the external auditory meatus |
| Continuous vs. intermittent | Continuous drainage with intermittent clamping (q1h for 5 min) to check ICP. Alternatively, intermittent drainage when ICP > 22 |
| Volume | Drain 3–5 mL at a time; typical daily output 100–250 mL/day |
| Complications | Infection (5–15%; reduced with antibiotic-impregnated catheters), hemorrhage (1–2%), overdrainage (can cause upward herniation in posterior fossa lesions or contralateral hematoma expansion) |
| Duration | Continue as long as needed; wean by gradually raising the drainage level |
3.1.2 Hyperosmolar Therapy
Mannitol
| Parameter | Detail |
|---|---|
| Bolus dose | 0.25–1 g/kg IV (20% solution) over 15–20 min |
| Typical adult dose | 50–100 g (250–500 mL of 20% mannitol) |
| Onset | 15–30 minutes |
| Duration | 2–6 hours |
| Repeat dosing | q4–6h PRN for ICP > 22 mmHg |
| Monitoring | Serum osmolality q6h. Hold if serum osmolality > 320 mOsm/L |
| Mechanism | Osmotic gradient draws water from brain parenchyma into vascular space; also reduces blood viscosity → reflex vasoconstriction → reduced cerebral blood volume |
| Cautions | Osmotic diuresis → hypovolemia and hypotension; rebound ICP elevation if BBB disrupted (mannitol crosses into brain tissue); hypokalemia; renal tubular damage with prolonged use |
| Contraindications | Hypovolemia, hypotension (SBP < 90), renal failure, serum osmolality > 320 |
Hypertonic Saline
| Concentration | Dose | Route | Notes |
|---|---|---|---|
| 23.4% | 30 mL IV bolus over 10–20 min | Central line preferred (may use large-bore peripheral for emergency) | Most concentrated; most rapid ICP reduction; used for acute herniation |
| 3% | 150–250 mL (5 mL/kg in children) IV bolus over 10–20 min; may use continuous infusion 0.5–2 mL/kg/hr | Peripheral or central line | Most commonly used concentration for both bolus and infusion |
| 5% | 100–150 mL IV bolus | Peripheral or central line | Intermediate concentration |
| 7.5% | 2 mL/kg IV over 10–20 min | Central line preferred | Used in some prehospital and military protocols |
Hypertonic Saline Monitoring and Targets:
| Parameter | Target/Limit |
|---|---|
| Serum sodium | Target 145–155 mEq/L for ongoing therapy; maximum 160 mEq/L |
| Serum osmolality | Maximum 360 mOsm/L (higher tolerance than mannitol) |
| Rate of sodium change | Increase no faster than 8–10 mEq/L per 24 hours (avoid osmotic demyelination) unless emergent herniation |
| Discontinuation | Taper slowly to avoid rebound cerebral edema |
Mannitol vs. Hypertonic Saline
| Feature | Mannitol | Hypertonic Saline |
|---|---|---|
| ICP reduction | Effective | Effective — may be slightly superior6 |
| Effect on blood pressure | Decreases (osmotic diuresis) | Increases (volume expansion) |
| Effect on intravascular volume | Decreases | Increases |
| Osmolality ceiling | 320 mOsm/L | 360 mOsm/L |
| Preferred setting | Stable hemodynamics; adequate volume status | Hypotension; hypovolemia; acute herniation |
| Rebound ICP | More common (crosses disrupted BBB) | Less common |
| Route | Peripheral IV (20% solution) | Central preferred for ≥ 3% bolus (peripheral acceptable for 3% infusion and emergency bolus) |
3.2 Tier 2 — Second-Line ICP-Lowering Therapies
Initiate when ICP remains > 22 mmHg despite Tier 1 measures.
3.2.1 Moderate Hyperventilation
| Parameter | Detail |
|---|---|
| Target PaCO2 | 30–35 mmHg |
| Mechanism | Hypocapnia → cerebral arteriolar vasoconstriction → reduced cerebral blood volume → reduced ICP |
| Duration | Temporary measure only; effectiveness wanes after 4–6 hours due to CSF bicarbonate equilibration |
| Monitoring | Continuous ETCO2; confirm with ABG. If available, monitor jugular venous oxygen saturation (SjvO2) or brain tissue oxygen (PbtO2) to detect cerebral ischemia |
| Cautions | PaCO2 < 30 mmHg should be avoided (Level III recommendation) due to risk of cerebral ischemia. Never use prophylactically, especially in first 24 hours1 |
3.2.2 Increased Hyperosmolar Therapy
Escalate dosing and frequency of mannitol or hypertonic saline, staying within osmolality and sodium limits.
3.2.3 Neuromuscular Blockade (Paralysis)
| Agent | Loading Dose | Infusion | Notes |
|---|---|---|---|
| Cisatracurium | 0.15–0.2 mg/kg IV | 1–3 mcg/kg/min | Organ-independent metabolism (Hofmann elimination); preferred in renal/hepatic dysfunction |
| Vecuronium | 0.1 mg/kg IV | 0.05–0.1 mg/kg/hr | Alternative agent |
| Rocuronium | 0.6–1.2 mg/kg IV | 0.3–0.6 mg/kg/hr | Can be reversed with sugammadex |
Rationale: Eliminates shivering, coughing, ventilator dyssynchrony, and muscle-generated increases in intrathoracic and intra-abdominal pressure, all of which raise ICP. Also reduces cerebral metabolic rate.
Requirements during paralysis:
- Continuous EEG monitoring (to detect subclinical seizures, which cannot be clinically identified in a paralyzed patient)
- Train-of-four (TOF) monitoring to titrate depth of blockade (target 1–2 twitches out of 4)
- Adequate sedation MUST be ensured before and during paralysis (BIS monitor if available)
- Aggressive DVT prophylaxis
- Eye care and positioning protocols
3.3 Tier 3 — Rescue Therapies for Refractory Intracranial Hypertension
Initiate when ICP remains > 22 mmHg despite maximal Tier 1 and 2 measures. These are high-risk interventions reserved for refractory cases.
3.3.1 Decompressive Craniectomy (DC)
Decompressive craniectomy involves removing a large section of the skull to allow outward expansion of the edematous brain, thereby reducing ICP. Two major RCTs have informed current practice.7 8 9
DECRA Trial (2011)
| Parameter | Detail |
|---|---|
| Population | Adults with severe diffuse TBI (no mass lesion > 25 mL), ICP > 20 mmHg for > 15 min refractory to Tier 1 measures |
| Intervention | Early bifrontotemporoparietal decompressive craniectomy vs. continued medical management |
| Primary outcome | Unfavorable outcome (GOS-E 1–4) at 6 months: 70% DC vs. 51% medical (p = 0.02) |
| ICP reduction | DC effectively reduced ICP |
| Mortality | 19% DC vs. 18% medical (no difference) |
| Interpretation | Early DC for diffuse TBI with moderate ICP elevation reduced ICP but increased unfavorable outcomes. However, criticized for low ICP threshold (> 20 for only 15 min), early timing, and surgical technique (bifrontal)7 |
RESCUEicp Trial (2016)
| Parameter | Detail |
|---|---|
| Population | Adults with TBI (any type including mass lesions) with refractory ICP > 25 mmHg for 1–12 hours despite maximal medical management (including barbiturates as option) |
| Intervention | Decompressive craniectomy (large, ≥ 12 × 15 cm) vs. continued medical management |
| Primary outcome | GOS-E at 6 months — DC: lower mortality (26.9% vs. 48.9%, p < 0.001) BUT higher rate of vegetative state (8.5% vs. 2.1%) |
| ICP reduction | DC more effectively reduced ICP |
| Favorable outcome (upper severe disability or better) | 42.8% DC vs. 34.6% medical (not statistically significant at 6 months; difference emerged at 12 months) |
| 12-month outcomes | More survivors in DC group achieved favorable outcomes at 12 months compared to 6 months |
| Interpretation | DC is a life-saving procedure for refractory ICP that reduces mortality but increases the proportion of survivors with severe disability. Patient/family counseling about expected outcomes is essential8 |
Current Recommendations for Decompressive Craniectomy
| Recommendation | Detail | Evidence |
|---|---|---|
| DC for refractory ICP | Large (≥ 12 × 15 cm) frontotemporal DC is recommended as a last-tier option for sustained ICP > 22 mmHg refractory to maximal medical management | Level IIA9 |
| Surgical technique | Large bone flap (at least 12 × 15 cm or 15-cm diameter). Small craniectomies are inadequate and associated with higher complication rates | Level III |
| Timing | After failure of Tier 1 and 2 measures; earlier DC may be considered when clinical/imaging trajectory is clearly deteriorating | Expert recommendation |
| Bifrontal DC | May be considered for diffuse bilateral swelling, but evidence less favorable than unilateral DC (DECRA) | Level IIA |
| Primary DC | DC performed at the time of surgical evacuation of a mass lesion, when intraoperative brain swelling is severe | Common clinical practice; limited trial data |
| Cranioplasty | Replacement of bone flap typically performed 6–12 weeks after DC; earlier cranioplasty (within 3 months) may improve CSF dynamics and neurologic recovery | Observational data |
3.3.2 Barbiturate Coma (Pentobarbital Protocol)
High-dose barbiturate therapy is used as a last-resort medical intervention for refractory intracranial hypertension.1 10
| Phase | Protocol |
|---|---|
| Loading dose | Pentobarbital 10 mg/kg IV over 30 minutes, then 5 mg/kg IV each hour × 3 doses |
| Maintenance infusion | 1–4 mg/kg/hr IV, titrated to ICP < 22 mmHg |
| EEG target | Burst suppression pattern (3–5 bursts per minute). Increasing dose beyond burst suppression does NOT provide additional ICP benefit |
| Alternative agent | Thiopental 2.5–5 mg/kg IV loading, then 3–5 mg/kg/hr (less commonly used in North America; more common in Europe) |
Critical Monitoring Requirements:
| Parameter | Requirement |
|---|---|
| Continuous EEG | Mandatory — to confirm burst suppression and detect seizures |
| Continuous arterial BP monitoring | Mandatory — hypotension is the most common and dangerous side effect |
| Vasopressor support | Almost always required (norepinephrine, phenylephrine, or vasopressin). Ensure adequate preload before initiating barbiturates |
| Cardiac output monitoring | Recommended (PA catheter or noninvasive cardiac output monitor) |
| Core temperature | Barbiturates cause hypothermia; monitor and maintain normothermia unless intentional hypothermia is also being used |
| Drug levels | Pentobarbital level 30–50 mcg/mL correlates with burst suppression; levels > 50 increase toxicity without additional ICP benefit |
Complications of Barbiturate Coma:
| Complication | Management |
|---|---|
| Hypotension (most common) | Vasopressors, volume resuscitation |
| Cardiac depression | Dobutamine if significant myocardial depression |
| Immunosuppression | Monitor for nosocomial infections |
| Paralytic ileus | Hold enteral feeds; consider parenteral nutrition |
| Hypothermia | Active warming if unintended |
| Prolonged sedation | Very long half-life; discontinue 24–48 hours before neurologic assessment |
Withdrawal: Taper slowly over 24–48 hours once ICP has been controlled for 24–48 hours. Abrupt discontinuation may cause rebound ICP elevation and withdrawal seizures.
3.3.3 Therapeutic Hypothermia — Eurotherm3235 Trial
| Parameter | Detail |
|---|---|
| Eurotherm3235 Trial (2015) | RCT of prophylactic hypothermia (32–35°C) as a first-line treatment (not rescue) for elevated ICP in severe TBI11 |
| Result | Trial stopped early for harm: hypothermia group had worse 6-month outcomes (GOS-E, p = 0.03) |
| POLAR Trial (2018) | Prophylactic hypothermia (33°C for 72h) initiated prehospital: no difference in favorable neurological outcome at 6 months, but potential benefit not ruled out12 |
| Current Recommendation | Prophylactic hypothermia is NOT recommended as a primary ICP treatment. Targeted temperature management (TTM) at 35–36°C may be considered as a last-tier adjunct for refractory ICP, but evidence is limited |
| Practical use | Avoid active rewarming in hypothermic patients; if used as rescue, target 33–35°C; rewarm slowly (0.25°C per hour maximum) to avoid rebound ICP |
4. Surgical Indications by Injury Type
4.1 Epidural Hematoma (EDH)
| Feature | Detail |
|---|---|
| Pathology | Hemorrhage between dura and skull, most commonly from middle meningeal artery (temporal region). May also be venous (dural sinus, diploic veins) |
| Classic presentation | “Lucid interval” — transient improvement after initial LOC followed by rapid deterioration; present in only ~20–30% of cases |
| Mortality | < 5% with timely surgical evacuation; > 50% if herniation before surgery |
Surgical Indications for EDH13
| Indication | Criteria |
|---|---|
| Surgical evacuation indicated | EDH volume > 30 mL regardless of GCS |
| EDH thickness > 15 mm | |
| Midline shift > 5 mm | |
| GCS ≤ 8 with any EDH and anisocoria (pupillary asymmetry) | |
| Neurological deterioration (GCS decline ≥ 2 points) attributable to EDH | |
| Timing | Operate within 60–120 minutes of neurological deterioration; faster is better for patients with pupillary abnormalities |
| Nonoperative management may be considered | EDH < 30 mL AND < 15 mm thick AND < 5 mm midline shift AND GCS > 8 with no focal neurological deficit. Requires serial CT and close neurological monitoring in a neurosurgical center |
4.2 Acute Subdural Hematoma (aSDH)
| Feature | Detail |
|---|---|
| Pathology | Hemorrhage between dura and arachnoid, usually from torn bridging veins (cortical veins draining into dural sinuses). Often associated with significant underlying brain injury |
| Mortality | 40–60% overall for acute SDH requiring surgery; higher in elderly and anticoagulated patients |
| Prognosis | Worse than EDH due to higher frequency of associated primary brain injury |
Surgical Indications for Acute SDH13
| Indication | Criteria |
|---|---|
| Surgical evacuation indicated | SDH thickness > 10 mm |
| Midline shift > 5 mm | |
| GCS decline ≥ 2 points from time of injury to hospital | |
| ICP > 22 mmHg | |
| GCS ≤ 8 with anisocoria or fixed dilated pupil(s) | |
| Timing | Operate within 4 hours of injury for best outcomes. Each hour of delay beyond 4 hours increases mortality by ~5–10%. Patients with GCS ≤ 8 and anisocoria should be in the operating room within 2 hours |
| Surgical technique | Large craniotomy with dural opening, evacuation of hematoma, hemostasis. Consider leaving bone flap off (converting to decompressive craniectomy) if intraoperative brain swelling is present |
| Nonoperative management | SDH < 10 mm thick AND < 5 mm midline shift AND no neurological deterioration AND ICP < 22 mmHg. Serial CT and neurological monitoring required |
4.3 Depressed Skull Fracture
Surgical Indications14
| Indication for Surgical Elevation | Detail |
|---|---|
| Open depressed fracture | Fracture with overlying scalp laceration — contamination risk; debridement and elevation indicated in most cases |
| Depression greater than the thickness of the skull (full-thickness table width) | Standard surgical indication |
| Dural penetration | Requires dural repair |
| Significant intracranial hematoma | Evacuate mass lesion |
| Frontal sinus involvement with posterior wall fracture | Risk of CSF leak, meningitis, mucocele |
| Cosmetic deformity | May warrant delayed elevation |
| Neurological deficit attributable to fracture | Surgical exploration indicated |
| Nonoperative Management Acceptable | Detail |
|---|---|
| Closed depressed fracture with depression ≤ skull thickness, no neurological deficit, no intracranial hematoma | Serial imaging and clinical follow-up |
Antibiotic prophylaxis for open depressed fractures (including basilar skull fractures with CSF leak) is recommended by most centers, though evidence is limited. A first-generation cephalosporin (cefazolin 2 g IV q8h) is commonly used.
4.4 Posterior Fossa Lesions
Posterior fossa hemorrhages (epidural, subdural, or intraparenchymal) are surgical emergencies because the posterior fossa has minimal space for expansion, and brainstem compression can occur rapidly.15
| Indication for Surgical Evacuation |
|---|
| Any posterior fossa mass lesion with neurological deterioration |
| Posterior fossa hematoma with brainstem compression on CT |
| Fourth ventricle effacement or obstruction (obstructive hydrocephalus) |
| Hematoma thickness > 3 cm (cerebellar hemorrhage) |
| GCS deterioration attributable to posterior fossa lesion |
Critical Warning: Posterior fossa lesions may deteriorate catastrophically with minimal warning. Even small hematomas can cause fatal brainstem compression. Neurosurgical consultation should be obtained emergently, and the threshold for surgical intervention should be low. EVD placement alone may be insufficient and can precipitate upward herniation if performed without concurrent posterior fossa decompression.15
4.5 Intraparenchymal Hemorrhage / Contusions
| Indication for Surgical Evacuation |
|---|
| Progressive neurological deterioration attributable to the lesion |
| Medically refractory intracranial hypertension |
| Frontal or temporal contusion > 20 mL with ≥ 5 mm midline shift or cisternal compression in patients with GCS 6–8 |
| Any intraparenchymal lesion > 50 mL |
| GCS 6–8 with signs of mass effect on CT (midline shift, cisternal compression, or loss of gray-white differentiation) |
Contusion Blossoming: Traumatic contusions commonly expand (“blossom”) over the first 24–72 hours. Repeat CT should be obtained if there is any clinical deterioration, and serial imaging should be considered at 6–8 hours after injury for patients with contusions.13
5. Practical ICP Management Algorithm — Summary
The following table summarizes the complete tiered approach.
| Tier | Intervention | Key Details | ICP Target |
|---|---|---|---|
| 0 | Foundational measures | HOB 30°, midline head, sedation/analgesia, normothermia, normocapnia, Na 140–150, glucose 100–180, seizure prophylaxis | < 22 mmHg |
| 1 | CSF drainage (EVD) | Drain against 10–15 cmH2O; 3–5 mL boluses or continuous drainage | < 22 mmHg |
| 1 | Hyperosmolar therapy (standard dosing) | Mannitol 0.25–1 g/kg bolus q4–6h (osm < 320) OR HTS 3% 150–250 mL bolus or 23.4% 30 mL (Na < 160) | < 22 mmHg |
| 2 | Moderate hyperventilation | PaCO2 30–35 mmHg; temporary; monitor PbtO2/SjvO2 if available | < 22 mmHg |
| 2 | Escalated hyperosmolar therapy | Higher doses, more frequent dosing, higher Na/osm targets | < 22 mmHg |
| 2 | Neuromuscular blockade | Cisatracurium or vecuronium infusion; requires continuous EEG and TOF monitoring | < 22 mmHg |
| 3 | Decompressive craniectomy | Large bone flap ≥ 12 × 15 cm; see DECRA/RESCUEicp evidence above | < 22 mmHg |
| 3 | Barbiturate coma | Pentobarbital 10 mg/kg load → 5 mg/kg/hr × 3h → 1–4 mg/kg/hr; EEG burst suppression | < 22 mmHg |
| 3 | Therapeutic hypothermia (cautious) | 33–35°C; NOT first-line; see Eurotherm3235 evidence; rewarm slowly | < 22 mmHg |
6. Special Considerations in ICP Management
6.1 Lumbar Drainage
In select patients with communicating hydrocephalus and refractory ICP, lumbar CSF drainage may be considered as an adjunct to EVD drainage. This is typically used when the EVD is draining poorly due to compressed ventricles.16
| Precaution | Detail |
|---|---|
| Absolute contraindication | Obstructive hydrocephalus, posterior fossa mass lesion, midline shift > 5 mm |
| Drainage rate | 5–10 mL/hr |
| Risk | Downward herniation if used inappropriately |
6.2 Metabolic Suppression with Propofol
Propofol infusion at doses of 100–200 mcg/kg/min reduces cerebral metabolic rate and may lower ICP. However, propofol infusion syndrome (PRIS) is a rare but potentially fatal complication seen with prolonged high-dose infusions.17
| PRIS Feature | Detail |
|---|---|
| Risk factors | Dose > 80 mcg/kg/min for > 48 hours, critical illness, high catecholamine states |
| Clinical features | Metabolic acidosis (lactic acidosis), rhabdomyolysis, hyperkalemia, cardiac failure, renal failure, lipemia |
| Monitoring | CK and triglycerides q24h; lactate if suspicion |
| Management | Discontinue propofol immediately; supportive care; may require ECMO for cardiac failure |
6.3 Indomethacin
Indomethacin (0.5–1 mg/kg IV bolus, then 0.5 mg/kg/hr infusion) causes cerebral vasoconstriction and can rapidly reduce ICP. It is sometimes used as a rescue therapy in refractory cases. However, evidence is limited to case series, and there is a risk of cerebral ischemia. Not routinely recommended.18
Carney N, Totten AM, O’Reilly C, et al. “Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition.” Neurosurgery. 2017;80(1):6-15. DOI: 10.1227/NEU.0000000000001432 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
ACS TQIP. “ACS TQIP Best Practices in the Management of Traumatic Brain Injury.” American College of Surgeons. 2015. URL: https://www.facs.org/quality-programs/trauma/quality/best-practices-guidelines/ ↩︎ ↩︎ ↩︎
Chesnut RM, Temkin N, Carney N, et al. “A trial of intracranial-pressure monitoring in traumatic brain injury.” N Engl J Med. 2012;367(26):2471-2481. DOI: 10.1056/NEJMoa1207363 ↩︎
Steiner LA, Czosnyka M, Piechnik SK, et al. “Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury.” Crit Care Med. 2002;30(4):733-738. DOI: 10.1097/00003246-200204000-00002 ↩︎
Stocchetti N, Maas AIR. “Traumatic intracranial hypertension.” N Engl J Med. 2014;370(22):2121-2130. DOI: 10.1056/NEJMra1208708 ↩︎
Kamel H, Navi BB, Nakagawa K, et al. “Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials.” Crit Care Med. 2011;39(3):554-559. DOI: 10.1097/CCM.0b013e318206b9be ↩︎
Cooper DJ, Rosenfeld JV, Murray L, et al. “Decompressive craniectomy in diffuse traumatic brain injury.” N Engl J Med. 2011;364(16):1493-1502. DOI: 10.1056/NEJMoa1102077 ↩︎ ↩︎
Hutchinson PJ, Kolias AG, Timofeev IS, et al. “Trial of decompressive craniectomy for traumatic intracranial hypertension.” N Engl J Med. 2016;375(12):1119-1130. DOI: 10.1056/NEJMoa1605215 ↩︎ ↩︎
Hawryluk GWJ, Rubiano AM, Totten AM, et al. “Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations.” Neurosurgery. 2020;87(3):427-434. DOI: 10.1093/neuros/nyaa278 ↩︎ ↩︎
Majdan M, Mauritz W, Wilbacher I, et al. “Barbiturates use and its effects in patients with severe traumatic brain injury in five European countries.” J Neurotrauma. 2013;30(1):23-29. DOI: 10.1089/neu.2012.2554 ↩︎
Andrews PJD, Sinclair HL, Rodriguez A, et al. “Hypothermia for intracranial hypertension after traumatic brain injury.” N Engl J Med. 2015;373(25):2403-2412. DOI: 10.1056/NEJMoa1507581 ↩︎
Cooper DJ, Nichol AD, Bailey M, et al. “Effect of early sustained prophylactic hypothermia on neurologic outcomes among patients with severe traumatic brain injury: the POLAR randomized clinical trial.” JAMA. 2018;320(21):2211-2220. DOI: 10.1001/jama.2018.17075 ↩︎
Bullock MR, Chesnut R, Ghajar J, et al. “Surgical management of acute epidural hematomas.” Neurosurgery. 2006;58(3 Suppl):S7-S15. DOI: 10.1227/01.NEU.0000210363.91172.A8 ↩︎ ↩︎ ↩︎
Bullock MR, Chesnut R, Ghajar J, et al. “Surgical management of depressed cranial fractures.” Neurosurgery. 2006;58(3 Suppl):S56-S60. DOI: 10.1227/01.NEU.0000210367.14043.0E ↩︎
Dahdaleh NS, Dlouhy BJ, Viljoen SV, et al. “Clinical and radiographic predictors of neurological outcome following posterior fossa decompression for spontaneous cerebellar hemorrhage.” J Clin Neurosci. 2012;19(9):1236-1241. DOI: 10.1016/j.jocn.2011.11.033 ↩︎ ↩︎
Tuettenberg J, Czabanka M, Horn P, et al. “Clinical evaluation of the safety and efficacy of lumbar cerebrospinal fluid drainage for the treatment of refractory increased intracranial pressure.” J Neurosurg. 2009;110(6):1200-1208. DOI: 10.3171/2008.10.JNS08293 ↩︎
Roberts RJ, Barletta JF, Fong JJ, et al. “Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.” Crit Care. 2009;13(5):R169. DOI: 10.1186/cc8145 ↩︎
Godoy DA, Rabinstein AA, Biestro A, et al. “Effects of indomethacin test on intracranial pressure and cerebral hemodynamics in patients with refractory intracranial hypertension.” Neurology. 2019;93(18):e1737-e1744. DOI: 10.1212/WNL.0000000000008450 ↩︎